Being aware that dealing with all the aspects of IFN biology in cancer may result reductive, this review presents a comprehensive overview of the latest findings regarding IFN cell signaling and its clinical administration as non-specific immunotherapy, with particular attention given to CRC and melanoma. This evidence concerns the gene IFNA1 and colorectal carcinoma.